Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.30 – $3.65
32% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.75B | $1.83B | $1.89B | $2.04B | $2.07B | $2.14B | $2.29B | $2.49B |
| Cost of revenue | $846.0M | $871.6M | $875.5M | $915.2M | $968.6M | $941.8M | $1.01B | $1.12B |
| Gross profit | $904.0M | $955.6M | $1.02B | $1.12B | $1.12B | $1.20B | $1.28B | $1.38B |
| Gross margin | 51.7% | 52.3% | 53.8% | 55.1% | 53.9% | 56.0% | 56.1% | 55.2% |
| R&D | $46.6M | $53.8M | $82.4M | $94.5M | $92.0M | $110.4M | $111.7M | $115.5M |
| Operating income | $259.4M | $96.9M | $211.0M | $203.6M | $207.3M | $262.7M | $324.9M | $416.1M |
| EBITDA | $440.8M | $321.5M | $448.7M | $395.5M | $450.5M | $455.5M | $540.2M | $645.0M |
| Net income | $221.6M | $9.8M | $112.5M | $117.6M | $62.9M | $130.3M | $190.5M | $178.9M |
| Net margin | 12.7% | 0.5% | 5.9% | 5.8% | 3.0% | 6.1% | 8.3% | 7.2% |
| EPS (diluted) | 0.11 | 0.01 | 0.06 | 0.06 | 0.03 | 0.06 | 0.09 | 0.09 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $0.20 | $0.19–$0.20 | 1 |
| 2027 | $2.7B | $0.22 | $0.22–$0.23 | 1 |
| 2028 | $2.9B | $0.25 | $0.24–$0.25 | 1 |
| 2029 | $3.1B | $0.28 | $0.27–$0.28 | 1 |
Forward consensus · source: Financial Modeling Prep
CONVATEC GRP PLC ORD
No one on the platform currently holds CNVVF.
No tracked institution reports a position in CNVVF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-17 | $0.0397 | 2026-05-28 |
| 2025-08-22 | $0.0140 | 2025-10-01 |
| 2025-04-22 | $0.0364 | 2025-05-29 |
| 2024-08-23 | $0.0142 | 2024-10-04 |
| 2024-04-25 | $0.0352 | 2024-05-23 |
| 2023-08-17 | $0.0138 | 2023-09-28 |
| Execution date | Ratio |
|---|---|
| 2023-08-17 | 161.14-for-160.14 |
| 2023-04-10 | 61.49-for-60.49 |
| 2022-08-25 | 155.5-for-154.5 |
| 2022-03-31 |
No one on the platform has traded CNVVF yet.
| $5.6B |
| — |
| RADLYRaia Drogasil S.A. | $3.44 | +3.93% | $6.0B | — |
| SHPMYShanghai Pharmaceuticals Holding Co., Ltd | $7.34 | +0.00% | $5.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 69.09-for-68.09 |
| 2021-09-02 | 184.95-for-183.95 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 28.9× earnings vs its 40.0× historical median P/E.
Fair value ≈ $3.78 · price $2.73 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.